

CHANGE OF REGISTERED OFFICE

Australian-based reproductive biotechnology company, Memphasys Limited (ASX: MEM), advise that effective 3 June 2024, the Company has changed its registered office and principal place of business.

The new address is Level 1 34-36 Richmond Rd, Homebush NSW 2140 Australia

This announcement has been approved for release by the CEO of Memphasys Limited.

ENDS

For further information, please contact:

Dr David Ali

Managing Director / Chief Executive Officer

Memphasys Limited

Tel: +61 2 8415 7300

E: david.ali@memphasys.com

About Memphasys

Memphasys Limited (ASX: MEM) specialises in reproductive biotechnology for high value commercial applications. Reproductive biotechnology products in development include medical devices, *in vitro* diagnostics, and new proprietary media. The Company's patented bio-separation technology, utilised by the Company's most advanced product, the Felix™ System, combines electrophoresis with proprietary size exclusion membranes to separate the most viable sperm cells for human artificial reproduction.

Website: www.memphasys.com

The Felix™ System is a registered trademark of Memphasys Limited. All rights reserved.